Formations of, Acquisitions by, and Mergers of Bank Holding Companies, 42815 [2017-19211]
Download as PDF
Federal Register / Vol. 82, No. 175 / Tuesday, September 12, 2017 / Notices
unauthorized access to sensitive
customer information, issues of
confidentiality may arise if the Board
were to obtain a copy of a customer
notice during the course of an
examination, a copy of a SAR, or other
sensitive customer information. In such
cases, the information would likely be
exempt from disclosure to the public
under the Freedom of Information Act
(5 U.S.C. 552(b)(3), (4), (6), and (8)).
Also, a federal employee is prohibited
by law from disclosing a SAR or the
existence of a SAR (31 U.S.C. 5318(g)).
Board of Governors of the Federal Reserve
System, September 6, 2017.
Ann E. Misback,
Secretary of the Board.
[FR Doc. 2017–19217 Filed 9–11–17; 8:45 am]
BILLING CODE 6210–01–P
Board of Governors of the Federal Reserve
System, September 6, 2017.
Yao-Chin Chao,
Assistant Secretary of the Board.
FEDERAL RESERVE SYSTEM
pmangrum on DSK3GDR082PROD with NOTICES1
Formations of, Acquisitions by, and
Mergers of Bank Holding Companies
[FR Doc. 2017–19211 Filed 9–11–17; 8:45 am]
The companies listed in this notice
have applied to the Board for approval,
pursuant to the Bank Holding Company
Act of 1956 (12 U.S.C. 1841 et seq.)
(BHC Act), Regulation Y (12 CFR part
225), and all other applicable statutes
and regulations to become a bank
holding company and/or to acquire the
assets or the ownership of, control of, or
the power to vote shares of a bank or
bank holding company and all of the
banks and nonbanking companies
owned by the bank holding company,
including the companies listed below.
The applications listed below, as well
as other related filings required by the
Board, are available for immediate
inspection at the Federal Reserve Bank
indicated. The applications will also be
available for inspection at the offices of
the Board of Governors. Interested
persons may express their views in
writing on the standards enumerated in
the BHC Act (12 U.S.C. 1842(c)). If the
proposal also involves the acquisition of
a nonbanking company, the review also
includes whether the acquisition of the
nonbanking company complies with the
standards in section 4 of the BHC Act
(12 U.S.C. 1843). Unless otherwise
noted, nonbanking activities will be
conducted throughout the United States.
Unless otherwise noted, comments
regarding each of these applications
must be received at the Reserve Bank
indicated or the offices of the Board of
Governors not later than October 5,
2017.
A. Federal Reserve Bank of Kansas
City (Dennis Denney, Assistant Vice
President) 1 Memorial Drive, Kansas
City, Missouri 64198–0001:
VerDate Sep<11>2014
15:19 Sep 11, 2017
Jkt 241001
1. Central Bancshares, Inc. to acquire,
through its newly formed subsidiaries,
CBI Midco, Inc. and CBI Merger Sub,
Inc., all of Cambridge, Nebraska, up to
100 percent of the voting shares of
Republic Corporation, and thereby
indirectly acquire United Republic
Bank, both of Omaha, Nebraska.
In connection with this application
CBI Midco, Inc. and CBI Merger Sub,
Inc., have applied to become bank
holding companies.
B. Federal Reserve Bank of San
Francisco (Gerald C. Tsai, Director,
Applications and Enforcement) 101
Market Street, San Francisco, California
94105–1579:
1. Pacific Premier Bancorp, Inc.; to
acquire 100 percent of Plaza Bancorp,
and thereby indirectly acquire Plaza
Bank, all of Irvine, California.
BILLING CODE 6210–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2017–N–4765]
Center for Devices and Radiological
Health Premarket Approval Application
Critical to Quality Pilot Program
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration’s (FDA or Agency or we)
Center for Devices and Radiological
Health (CDRH or Center), Office of
Compliance (OC) and Office of In Vitro
Diagnostics and Radiological Health
(OIR) is announcing its Premarket
Approval Application Critical to Quality
(PMA CtQ) pilot program. Participation
in the PMA CtQ pilot program is
voluntary and the program aims to
evaluate device design and
manufacturing process quality
information early on to assist FDA in its
review of the PMA manufacturing
section and post-approval inspections.
This voluntary pilot program is part of
the FDA’s ongoing Case for Quality
effort to apply innovative strategies that
promote medical device quality and is
a joint effort between the FDA’s CDRH
and Office of Regulatory Affairs (ORA).
The pilot program is intended to
provide qualifying PMA applicants with
the option to engage FDA on
SUMMARY:
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
42815
development of CtQ controls for their
device and forego the standard PMA
preapproval inspection. FDA would in
turn, focus on the PMA applicant’s
implementation of the CtQ controls
during a postmarket inspection.
DATES: FDA is seeking participation in
the voluntary PMA CtQ pilot program
starting from September 29, 2017. See
the ‘‘Participation’’ section for
instructions on how to submit a request
to participate. This pilot program will
run from September 29, 2017, to
December 31, 2018. The voluntary PMA
CtQ pilot program will accept the first
nine participants with submissions that
meet the acceptance criteria.
ADDRESSES: You may submit comments
as follows:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
E:\FR\FM\12SEN1.SGM
12SEN1
Agencies
[Federal Register Volume 82, Number 175 (Tuesday, September 12, 2017)]
[Notices]
[Page 42815]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-19211]
-----------------------------------------------------------------------
FEDERAL RESERVE SYSTEM
Formations of, Acquisitions by, and Mergers of Bank Holding
Companies
The companies listed in this notice have applied to the Board for
approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C.
1841 et seq.) (BHC Act), Regulation Y (12 CFR part 225), and all other
applicable statutes and regulations to become a bank holding company
and/or to acquire the assets or the ownership of, control of, or the
power to vote shares of a bank or bank holding company and all of the
banks and nonbanking companies owned by the bank holding company,
including the companies listed below.
The applications listed below, as well as other related filings
required by the Board, are available for immediate inspection at the
Federal Reserve Bank indicated. The applications will also be available
for inspection at the offices of the Board of Governors. Interested
persons may express their views in writing on the standards enumerated
in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the
acquisition of a nonbanking company, the review also includes whether
the acquisition of the nonbanking company complies with the standards
in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted,
nonbanking activities will be conducted throughout the United States.
Unless otherwise noted, comments regarding each of these
applications must be received at the Reserve Bank indicated or the
offices of the Board of Governors not later than October 5, 2017.
A. Federal Reserve Bank of Kansas City (Dennis Denney, Assistant
Vice President) 1 Memorial Drive, Kansas City, Missouri 64198-0001:
1. Central Bancshares, Inc. to acquire, through its newly formed
subsidiaries, CBI Midco, Inc. and CBI Merger Sub, Inc., all of
Cambridge, Nebraska, up to 100 percent of the voting shares of Republic
Corporation, and thereby indirectly acquire United Republic Bank, both
of Omaha, Nebraska.
In connection with this application CBI Midco, Inc. and CBI Merger
Sub, Inc., have applied to become bank holding companies.
B. Federal Reserve Bank of San Francisco (Gerald C. Tsai, Director,
Applications and Enforcement) 101 Market Street, San Francisco,
California 94105-1579:
1. Pacific Premier Bancorp, Inc.; to acquire 100 percent of Plaza
Bancorp, and thereby indirectly acquire Plaza Bank, all of Irvine,
California.
Board of Governors of the Federal Reserve System, September 6,
2017.
Yao-Chin Chao,
Assistant Secretary of the Board.
[FR Doc. 2017-19211 Filed 9-11-17; 8:45 am]
BILLING CODE 6210-01-P